Due to the fact Pirfenidone is metabolised from the CYP1A2 enzyme pathway, any drug which inhibits this enzyme is likely to precipitate the toxicity of pirfenidone: concomitant therapy should be to be averted. lonapegsomatropin will reduce the extent or outcome of pirfenidone by affecting hepatic